NFE2L2 and Alzheimer disease: This is supported by data from preclinical models of AD, which indicate reduced brain Nrf2 expression levels (Carvalho et al., 2015; Liu et al., 2016; Manczak et al., 2018), with Nrf2 activation mitigating neuronal apoptosis and spatial memory impairment (Dong F. et al., 2017).